Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Endocrine Pharmacology

Protective effects of bendazac lysine on early experimental diabetic nephropathy in rats

Acta Pharmacologica Sinica volume 26, pages 721–728 (2005)Cite this article

Abstract

Aim:

To investigate the preventive and protective effects of bendazac lysine (BDL) on experimental early diabetic nephropathy (DN) rats.

Methods:

After an early DN model was induced by streptozotocin, rats were administered BDL at doses of 100, 200, and 400 mg/kg for 8 weeks. Blood glucose, microalbuminuria, kidney index, total antioxidative capacity, laminin, advanced glycation end products (AGE), aldose reductase (AR) activity, and the relative quantity of transforming growth factor β1 (TGF-β1) mRNA were measured by different methods. The ultrastructural morphology was observed by transmission electron microscope.

Results:

The physical behaviors of early DN rats were hypopraxia, cachexia, and polyuria, while those treated with high doses of BDL were vibrant and vigorous. For BDL-treated DN rats, when compared with vehicle-treated DN rats, the blood glucose level and the intensity of oxidative stress were ameliorated. Also, the micro albuminuria level, AGE either in serum or in renal, and AR activity were significantly reduced. Furthermore, the expression of TGF-β1 mRNA in the kidney cortex was declined and the thickness of glomerular base membrane was decreased significantly. The ultrastructure of glomerulus and mesangial matrix of BDL-treated DN rats were ameliorated.

Conclusion:

BDL has protective effects on several pharmacological targets in the progress of DN and is a potential drug for the prevention of early DN.

Download PDF

References

  1. Catherwood MA, Powell LA, Anderson P, McMaster D, Sharpe PC, Trimble ER . Glucose-induced oxidative stress in mesangial cells. Kidney Int 2002; 61: 599–608.

    CAS  Article  Google Scholar 

  2. Wautier JL, Guillausseau PJ . Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535–42.

    CAS  PubMed  Google Scholar 

  3. Cooper ME . Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957–72.

    CAS  Article  Google Scholar 

  4. Sharma K, McGowan Tracy A . TGF-β in diabetic kidney: role of novel signaling pathways. Cytokine Growth Factor Rev 2000; 11: 115–23.

    CAS  Article  Google Scholar 

  5. Liu BC, Chen Q, Luo DD, Sun J, Phillips AO, Ruan XZ, et al. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2003; 24: 67–73.

    Google Scholar 

  6. Balfour JA, Clissold SP . Bendazac lysine: a review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs 1990; 39: 575–96.

    CAS  Article  Google Scholar 

  7. Inliano G, Menzion M, Apponi-Battini G, Costagliola C . Inhibition of rat lens aldose reductase by bandazac-L-lysine salt. Enzyme 1989; 42: 235–7.

    Article  Google Scholar 

  8. Schmut O, Hofmann H . Studies on the activity of bendalina (bendazac L-lysine salt) as a scavenger of hydroxyl and superoxide radials. Wien Klin Wochenschr 1985; 97: 819–22.

    CAS  PubMed  Google Scholar 

  9. Marques C, Ramalho JS, Pereira P, Mota MC . Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac. Doc Ophthalmol 1995; 90: 395–404.

    CAS  Article  Google Scholar 

  10. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A . A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407–12.

    CAS  Article  Google Scholar 

  11. Das B, Srivastava SK . Purification and properties of aldose reductase and aldehyde reductase II from human erythrocyte. Arch Biochem Biophy 1985; 238: 670–9.

    CAS  Article  Google Scholar 

  12. Kaneto H, Morrissey J, Klahr S . Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993; 44: 313–21.

    CAS  Article  Google Scholar 

  13. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Lefebvre PJ . Metabolic control may influence the increased superoxide generation in diabetic serum. Diabetic Med 1991; 8: 540–2.

    CAS  Article  Google Scholar 

  14. Schmut, Fellinger C, Hofmann H . Bendazac lysine: a protective substance against oxygen-free radicals. In: D'Ermo F . Recent developments in the pharmacological treatment of cataract. Amsterdam: Kugler Publications; 1987. p 69–72.

    Google Scholar 

  15. Schleicher ED, Wagner E, Nerlich AG . Increased accumulation of the glycoxidation product Nɛ-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457–68.

    CAS  Article  Google Scholar 

  16. Ihm SH, Yoo HJ, Park SW, Ihm J . Effect of aminiguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism 1999; 48: 1141–5.

    CAS  Article  Google Scholar 

  17. Min C, Kang E, Yu SK, Shinn SH, Kim YS . Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diab Res Clin Pract 1999; 46: 197–202.

    CAS  Article  Google Scholar 

  18. Lewis BS, Harding JJ . The major metabolite of bendazac inhibits the glycosylation of soluble lens proteins: a possible mechanism for a delay in cataractogenesis. Exp Eye Res 1988; 47: 217–25.

    CAS  Article  Google Scholar 

  19. Lewis BS, Rixon KC, Harding JJ . Bendazac prevents cyanate binging to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract. Exp Eye Res 1986; 43: 973–9.

    CAS  Article  Google Scholar 

  20. Jandeleit-Dahm K, Cao ZM, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME . Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int 1999; 56 ( Suppl 71): S31–6.

    Article  Google Scholar 

  21. Montero A, Munger KA, Khan RZ, Valdivielso JM, Morrow JD, Guasch A, et al. F-2-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int 2000; 58: 1963–72.

    CAS  Article  Google Scholar 

  22. Yin XX, Zhang YD, Wu HW, Zhu X, Zheng XG, Jiang SJ, et al. Protective effects of Astragalus Sapoonin I on early stage of diabetic nephropathy in rats. J Pharmacol Sci 2004; 95: 256–66.

    CAS  Article  Google Scholar 

  23. Greene DA, Lattimer SA, Sima AAF . Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complicatins. N Engl J Med 1987; 316: 599–606.

    CAS  Article  Google Scholar 

  24. Ishii H, Tada H, Isogai S . An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured human mesangial cells. Diabetologia 1998; 41: 362–4.

    CAS  Article  Google Scholar 

  25. Suzuki K, Kawamura T, Sakakibara F, Sasaki H, Sano T, Sakamoto N, et al. Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myoinositol metabolism in human neutrophils. Diabet Med 1999; 16: 67–73.

    CAS  Article  Google Scholar 

  26. Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, et al. Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000; 23: 1539–44.

    CAS  Article  Google Scholar 

  27. Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R, Yasuda Y, et al. Aldose reductase inhibition ameliorates papillary light reflex and F-wave latency in patients with mild diabetic neuropathy. Diabetes Care 2001; 24: 1093–8.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Pharmacology, Nanjing Medical University, Nanjing, 210029, China

    Xiao-xing Yin, Yin-di Zhang, Jian-ping Shen, Li-min Li & Jun Qiu

  2. Department of Pathogenic Biology, Nanjing Medical University, Nanjing, 210029, China

    Hai-wei Wu & Xiang Zhu

  3. Department of Pathology, Nanjing Jing Ling Hospital, Nanjing, 210002, China

    Shao-jun Jiang & Xiao-gang Zheng

Authors
  1. Xiao-xing Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yin-di Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian-ping Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hai-wei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiang Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li-min Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shao-jun Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiao-gang Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiao-xing Yin or Yin-di Zhang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yin, Xx., Zhang, Yd., Shen, Jp. et al. Protective effects of bendazac lysine on early experimental diabetic nephropathy in rats. Acta Pharmacol Sin 26, 721–728 (2005). https://doi.org/10.1111/j.1745-7254.2005.00111.x

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1111/j.1745-7254.2005.00111.x

Keywords

  • bendazac lysine
  • diabetic nephropathies
  • blood glucose
  • oxidative stress

Further reading

Search

Advanced search

Quick links